Back to Search Start Over

Improving Lung Function in Severe Heterogenous Emphysema with the Spiration Valve System (EMPROVE). A Multicenter, Open-Label Randomized Controlled Clinical Trial.

Authors :
Criner GJ
Delage A
Voelker K
Hogarth DK
Majid A
Zgoda M
Lazarus DR
Casal R
Benzaquen SB
Holladay RC
Wellikoff A
Calero K
Rumbak MJ
Branca PR
Abu-Hijleh M
Mallea JM
Kalhan R
Sachdeva A
Kinsey CM
Lamb CR
Reed MF
Abouzgheib WB
Kaplan PV
Marrujo GX
Johnstone DW
Gasparri MG
Meade AA
Hergott CA
Reddy C
Mularski RA
Case AH
Makani SS
Shepherd RW
Chen B
Holt GE
Martel S
Source :
American journal of respiratory and critical care medicine [Am J Respir Crit Care Med] 2019 Dec 01; Vol. 200 (11), pp. 1354-1362.
Publication Year :
2019

Abstract

Rationale: Less invasive, nonsurgical approaches are needed to treat severe emphysema. Objectives: To evaluate the effectiveness and safety of the Spiration Valve System (SVS) versus optimal medical management. Methods: In this multicenter, open-label, randomized, controlled trial, subjects aged 40 years or older with severe, heterogeneous emphysema were randomized 2:1 to SVS with medical management (treatment) or medical management alone (control). Measurements and Main Results: The primary efficacy outcome was the difference in mean FEV <subscript>1</subscript> from baseline to 6 months. Secondary effectiveness outcomes included: difference in FEV <subscript>1</subscript> responder rates, target lobe volume reduction, hyperinflation, health status, dyspnea, and exercise capacity. The primary safety outcome was the incidence of composite thoracic serious adverse events. All analyses were conducted by determining the 95% Bayesian credible intervals (BCIs) for the difference between treatment and control arms. Between October 2013 and May 2017, 172 participants (53.5% male; mean age, 67.4 yr) were randomized to treatment ( n  = 113) or control ( n  = 59). Mean FEV <subscript>1</subscript> showed statistically significant improvements between the treatment and control groups-between-group difference at 6 and 12 months, respectively, of 0.101 L (95% BCI, 0.060-0.141) and 0.099 L (95% BCI, 0.048-0.151). At 6 months, the treatment group had statistically significant improvements in all secondary endpoints except 6-minute-walk distance. Composite thoracic serious adverse event incidence through 6 months was greater in the treatment group (31.0% vs. 11.9%), primarily due to a 12.4% incidence of serious pneumothorax. Conclusions: In patients with severe heterogeneous emphysema, the SVS shows significant improvement in multiple efficacy outcomes, with an acceptable safety profile.Clinical trial registered with www.clinicaltrials.gov (NCT01812447).

Details

Language :
English
ISSN :
1535-4970
Volume :
200
Issue :
11
Database :
MEDLINE
Journal :
American journal of respiratory and critical care medicine
Publication Type :
Academic Journal
Accession number :
31365298
Full Text :
https://doi.org/10.1164/rccm.201902-0383OC